Appili Therapeutics has concluded subject enrolment in its international Phase III PRESECO clinical trial of oral Avigan/Reeqonus (favipiravir) as a potential drug for Covid-19.
The trial enrolled 1,231 subjects from 38 trial centres across the US, Mexico, and Brazil.
Go deeper with GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
Developed by Fujifilm Toyama Chemical, Avigan/Reeqonus is a broad-spectrum oral antiviral drug.
It specifically hinders viral RNA-dependent ribonucleic acid (RNA) polymerase (sRdRP) with potent antiviral activity against single-stranded RNA viruses such as coronaviruses.
The company raised the enrolment targets to increase the number of patients and SARS-CoV-2 variant cases, including Delta variant, in the trial.
Appili commenced the trial in November 2020 to assess oral Avigan/Reeqonus as a potential at-home treatment for Covid-19.
US Tariffs are shifting - will you react or anticipate?
Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.
By GlobalDataThe double-blind, placebo-controlled, randomised, multicentre Phase III superiority trial is assessing the safety and efficacy of oral Avigan/Reeqonus as the early therapy for adult Covid-19 patients with mild-to-moderate symptoms.
Participants will comprise outpatients who were tested positive for Covid-19 within 72 hours of recruitment.
Subjects in the trial will administer the drug themselves in the at-home setting and the trial investigators will monitor them remotely.
The impact of oral antiviral on time to Covid-19 symptom resolution will be the primary goal of the trial.
Furthermore, the trial will assess the impact of the drug on disease progression to severe Covid-19.
It also comprises a viral shedding sub-study, which is analysing the impact of Avigan/Reeqonus on time to viral clearance.
Last week, Appili completed subject enrolment in the viral shedding sub-study portion of Avigan/Reeqonus in the US.
In addition, viral isolates will be sequenced for detecting SARS-CoV-2 variants in the PRESECO trial.
Appili Therapeutics CEO Armand Balboni said: “Completing enrolment in this large Phase III pivotal trial in just ten months is a tremendous accomplishment for Appili.
“With this major milestone now achieved, we have a clear path to completing the PRESECO data analysis in the coming weeks and determining if Avigan/Reeqonus has the potential to meet the urgent global clinical need for a safe and effective oral treatment for this deadly disease.”
Top-line results from the trial are expected in nearly 60 days.
